This article is part of the supplement: Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress

Open Access Open Badges Oral presentation

Etanercept in juvenile idiopathic arthritis: Who will benefit?

MH Otten1*, FHM Prince1, W Armbrust2, R ten Cate3, EPAH Hoppenreijs4, M Twilt13, Y Koopman-Keemink5, SL Gorter6, KM Dolman7, JF Swart7, JM van den Berg7, NM Wulffraat8, MAJ van Rossum7 and LWA van Suijlekom-Smit1

Author Affiliations

1 Department of Pediatrics/Pediatric Rheumatology, Rotterdam, The Netherlands

2 Department of Pediatrics/Pediatric Rheumatology, Groningen, The Netherlands

3 Department of Pediatrics/Pediatric Rheumatology, Leiden, The Netherlands

4 Department of Pediatrics/Pediatric Rheumatology, Nijmegen, The Netherlands

5 Department of Pediatrics/Pediatric Rheumatology, The Hague, The Netherlands

6 Department of Pediatrics/Pediatric Rheumatology, Maastricht, The Netherlands

7 Department of Pediatrics/Pediatric Rheumatology, Amsterdam, The Netherlands

8 Department of Pediatrics/Pediatric Rheumatology, Utrecht, The Netherlands

For all author emails, please log on.

Pediatric Rheumatology 2011, 9(Suppl 1):O28  doi:10.1186/1546-0096-9-S1-O28

The electronic version of this article is the complete one and can be found online at:

Published:14 September 2011

© 2011 Otten et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The pharmacological treatment approach for juvenile idiopathic arthritis (JIA) has changed substantially since the introduction of biologicals, with nowadays inactive disease as realistic treatment goal.


To identify factors at baseline which predict etanercept treatment response and subsequently optimize treatment strategies.


The Arthritis and Biologicals in Children Register (observational study, ongoing since 1999), includes all Dutch JIA-patients who used etanercept. Disease activity variables were retrieved prospectively at start of treatment, after 3 months, and yearly thereafter.


262 previously biologic-naive JIA-patients initiated etanercept; 71% female, 18% systemic-onset subtype. Median age at onset 6.9 (IQR 3.6-11.1) years, median follow-up 35.6 (IQR 17.4-53.6) months. In the long-term, the overall majority responded to etanercept and up to 40% reached inactive disease. Excellent response after 15 months (85 patients, 32%) was associated with low baseline disability (OR 0.49/point increase, 95%CI 0.33-0.74), fewer DMARDs used before etanercept (OR 0.64/DMARD used, 95%CI 0.43-0.95) and younger age at onset (OR 0.92/year, 95%CI 0.84-0.99); poor response (88 patients, 34%) was associated with female gender (OR 2.12, 95%CI 1.11-4.08) and systemic-onset subtype (OR 3.24, 95%CI 1.39-7.56). However, 24% of systemic-onset patients reached excellent response. Reasons for discontinuation: ineffectiveness in 78, adverse events (AEs) in 25, remission in 39 patients. Etanercept was well tolerated. Patients who developed AEs could not be identified at baseline.


Excellent response was associated with baseline low disability and less DMARD-use before etanercept. Therefore, the focus should be on strategies with early introduction of etanercept to improve outcomes for JIA. The role of etanercept for the systemic-onset subtype remains debatable.